Evaluation du projet SPAS-PMU REVIAC

Le projet REVIAC: Le projet REVIAC (Réinsertion vie active) est un projet de collaboration entre le Service de prévoyance et d'aides sociales (SPAS) et la Policlinique médicale universitaire (PMU) pour améliorer les possibilités de démarches de réinsertion chez les bénéficiaires du revenu d'insertion (RI) avec certificat d'incapacité de travail. En effet, certains bénéficiaires ont des certificats médicaux d'incapacité récurrents et les assistants sociaux (AS) ne peuvent entreprendre les démarches nécessaires. Le projet développé par le SPAS et la PMU comprend deux axesa : ? La création à la PMU d'une consultation pour les bénéficiaires du RI dont l'état de santé compromet toute démarche d'insertion/d'activation. ? Le développement de l'information et de la formation : a) des médecins, principalement de premier recours, sur les thématiques sociales liées au RI et le réseau socio-sanitaire existant, et b) des assistants sociaux sur les pratiques des médecins traitants. Les objectifs du projet sont : Encourager l'élaboration de projets favorisant l'autonomie des bénéficiaires (autonomie sociale comme professionnelle et financière), compatibles avec leur état de santé, réalistes et réalisables ; Apporter un soutien médical aux bénéficiaires entrant dans une démarche d'insertion ou en cours d'insertion, en collaboration avec leurs médecins traitants ; Fournir aux AS les informations nécessaires leur permettant d'initier, au besoin, une collaboration avec l'AI dans le cadre de mesures de prévention et d'insertion ; Permettre aux AS de diriger et accompagner les bénéficiaires dont l'état de santé est incompatible avec une démarche d'insertion vers d'autres types de mesures ou d'autres prises en charge plus adéquates (rentes AI, etc.) ; Améliorer la collaboration entre les médecins traitants des bénéficiaires et les assistants sociaux en charge de leur dossier ; Proposer, à terme, le développement de nouvelles mesures adaptées aux problématiques de santé des bénéficiaires

Multidrug-resistant HIV viral rebound during early syphilis: a case report

Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within the therapeutic range. Case presentation This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA. Conclusions This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological control with the potential of transmitting an extensively drug-resistant virus

Is a wearable sensor-based characterisation of gait robust enough to overcome differences between measurement protocols? A multi-centric pragmatic study in patients with multiple sclerosis

Inertial measurement units (IMUs) allow accurate quantification of gait impairment of people with multiple sclerosis (pwMS). Nonetheless, it is not clear how IMU-based metrics might be influenced by pragmatic aspects associated with clinical translation of this approach, such as data collection settings and gait protocols. In this study, we hypothesised that these aspects do not significantly alter those characteristics of gait that are more related to quality and energetic efficiency and are quantifiable via acceleration related metrics, such as intensity, smoothness, stability, symmetry, and regularity. To test this hypothesis, we compared 33 IMU-based metrics extracted from data, retrospectively collected by two independent centres on two matched cohorts of pwMS. As a worst-case scenario, a walking test was performed in the two centres at a different speed along corridors of different lengths, using different IMU systems, which were also positioned differently. The results showed that the majority of the temporal metrics (9 out of 12) exhibited significant between-centre differences. Conversely, the between-centre differences in the gait quality metrics were small and comparable to those associated with a test-retest analysis under equivalent conditions. Therefore, the gait quality metrics are promising candidates for reliable multi-centric studies aiming at assessing rehabilitation interventions within a routine clinical context

Highly Sensitive Magnetic Array-based Platform for Neuronal Signal Recording

This work presents a platform for the detection of the neuronal magnetic signal arising from the propagation of the action potential along the axon, via an array of highly sensitive magnetoresistive sensors and a low noise front-end electronic setup. We report the results of calculations and experiments for estimating the limit of detection of such platform in terms of minimum detectable magnetic field. Furthermore, an experimental setup for recording the magnetic signal in a brain slice is presented. (C) 2017 The Authors. Published by Elsevier Ltd

Towards a magnetoresistive platform for neural signal recording

A promising strategy to get deeper insight on brain functionalities relies on the investigation of neural activities at the cellular and sub-cellular level. In this framework, methods for recording neuron electrical activity have gained interest over the years. Main technological challenges are associated to finding highly sensitive detection schemes, providing considerable spatial and temporal resolution. Moreover, the possibility to perform non-invasive assays would constitute a noteworthy benefit. In this work, we present a magnetoresistive platform for the detection of the action potential propagation in neural cells. Such platform allows, in perspective, the in vitro recording of neural signals arising from single neurons, neural networks and brain slices

When food can make the difference : The case of elvitegravir-based co-formulation

Stribild should be administered under fed conditions to optimize drugs exposure. Here we assessed to what extent this advice is applied in the real life scenario by therapeutic drug monitoring in 75 HIV-infected patients given Stribild-based antiretroviral therapy. Fifty-three percent of our patients took Stribild at lunch/supper time, 23% in the morning with breakfast, and 24% middle in the morning or late in the evening. Twelve out of the 75 patients had unquantifiable elvitegravir concentrations, whereas in the remaining the levels were largely distributed. Wide inter-individual variability in the tenofovir, cobicistat and darunavir trough concentrations was also observed. In real life settings a significant proportion of patients took Stribild without food, namely in the mid-morning or late in the evening. This resulted in a wide inter-individual variability of antiretroviral drug trough concentrations. To avoid the risk for patients to experience suboptimal drug exposure, it is important that health professionals more convincingly advise their patients to take Stribild in fed conditions. On the other hand, the role of patient education and patient responsibility to correctly take the therapy should not be underestimated